InnoCare Pharma (FRA:33C) Cash-to-Debt : 6.10 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is InnoCare Pharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. InnoCare Pharma's cash to debt ratio for the quarter that ended in Dec. 2023 was 6.10.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, InnoCare Pharma could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for InnoCare Pharma's Cash-to-Debt or its related term are showing as below:

FRA:33C' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.34 Med: 3.38 Max: 7.19
Current: 6.1

During the past 7 years, InnoCare Pharma's highest Cash to Debt Ratio was 7.19. The lowest was 0.34. And the median was 3.38.

FRA:33C's Cash-to-Debt is ranked worse than
51.46% of 1539 companies
in the Biotechnology industry
Industry Median: 6.51 vs FRA:33C: 6.10

InnoCare Pharma Cash-to-Debt Historical Data

The historical data trend for InnoCare Pharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

InnoCare Pharma Cash-to-Debt Chart

InnoCare Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

2.09

3.38

4.92

7.19

6.10

InnoCare Pharma Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial												7.19	6.75	155.01	6.10	N/A

Competitive Comparison of InnoCare Pharma's Cash-to-Debt

For the Biotechnology subindustry, InnoCare Pharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InnoCare Pharma's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's Cash-to-Debt falls into.

InnoCare Pharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

InnoCare Pharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1056.267	/	(164.306	+	8.983)
	=	6.10

InnoCare Pharma's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1056.267	/	(164.306	+	8.983)
	=	6.10

InnoCare Pharma (FRA:33C) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

InnoCare Pharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (FRA:33C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

09969:Hong Kong 33C:Germany 688428:China

Address

No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206

Website

https://www.innocarepharma.com

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (FRA:33C) Headlines

No Headlines